Japanese pharmaceutical giant Otsuka [announced on March 27th](https://psychedelicalpha.com/news/breaking-otsuka-to-acquire-methylone-drug-developer-transcend-in-1-23b-deal/) that its U.S. subsidiary is acquiring Transcend Therapeutics for up to $1.225 billion — $700 million upfront plus $525 million contingent on sales milestones. Transcend's lead asset is TSND-201, a methylone analog under investigation for PTSD, generalized anxiety disorder, and major depressive disorder.
Methylone is an analog of MDMA. Transcend has been careful to avoid that framing in its public positioning — the company has gone out of its way to describe TSND-201 as distinct from psychedelics and hallucinogens — but the pharmacology is closely related. Dosing sessions in its Phase 2 program ran at least eight hours, patients received four weekly doses, and the drug has a half-life of around six hours. The protocol looks like MDMA-assisted therapy because it essentially is.
## Why this deal is notable
A $1.2 billion acquisition by a major pharma company is the largest deal the psychedelic-adjacent medicine space has seen. Otsuka makes Abilify and Rexulti — it knows the psychiatric drug market. The bet here is that even in the wake of the FDA's MDMA rejection, there's a regulatory path for entactogen-assisted therapy if the trial design is clean and the disclosure practices are better than Lykos's.
Phase 3 (EMPOWER-1, [NCT07456696](https://clinicaltrials.gov/study/NCT07456696)) has begun recruiting — 300 participants, randomized to one of two doses or placebo over four weekly sessions.
## The bigger picture
The Lykos rejection spooked the market. Several companies pulled back on timelines or pivoted away from compounds with overt psychedelic profiles. Otsuka's move — at this price, at this stage — is a signal that at least one major pharma player thinks the regulatory door isn't actually closed. They're just betting on a different key.